½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1446521

º»¿Î½º(Bone Wax) ½ÃÀå - ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Bone Wax Market Size, Share & Trends Analysis Report By Product (Absorbable, Non-absorbable), By Application (Orthopedic Surgery, Thoracic Surgery), By Material, By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º»¿Î½º ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ º»¿Î½º ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â¿¡ °ÉÃÄ 3.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 6,600¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¼¼°è °ñÀý ¹ß»ý·ü Áõ°¡´Â Á¦Ç° »ç¿ëÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. °ñ´Ù°øÁõÀº ƯÈ÷ °í°üÀý, ¼Õ¸ñ, ôÃßÀÇ °ñÀýÀ» ÃÊ·¡ÇÏ´Â ÁÖ¿ä À§Çè ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ±¹Á¦ °ñ´Ù°øÁõ Àç´Ü¿¡ µû¸£¸é 2050³â±îÁö ¾Æ½Ã¾Æ Àα¸´Â °ñ´Ù°øÁõÀÇ À¯º´·üÀÌ 50%¸¦ ÃÊ°úÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ °ñ´Ù°øÁõÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °üÀý¿°ÀÇ À¯º´·ü Áõ°¡°¡ ¾÷°è ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °üÀý¿°Àº °ñÁúÀÇ ¿­È­¸¦ ÃÊ·¡ÇÏ¿© °ñÀýÀÇ À§ÇèÀ» ´õ¿í Áõ°¡½Ãŵ´Ï´Ù. Institute for Health Metrics and Evaluation¿¡ µû¸£¸é 2050³â±îÁö ÀϹÝÀûÀÎ °üÀý¿°ÀÎ °ñ°üÀý¿°ÀÇ ¼¼°è À¯º´·üÀº 10¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2021³â 2¿ù¿¡ ¹ßÇ¥µÈ Elsevier BV(Science Direct)ÀÇ ¿¬±¸¿¡ µû¸£¸é, ¿µ±¹¿¡¼­´Â °ñ°üÀý¿° ȯÀÚÀÇ °ñÀý À¯º´·üÀÌ 1000¸í´ç 13.2¸íÀÎ ¹Ý¸é °ñ°üÀý¿°ÀÌ ¾Æ´Ô »ç¶÷ÀÇ À¯º´·üÀº 1000¸í´ç 8.5¸íÀ̾ú½À´Ï´Ù. Ä¡°úÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í Àç°Ç ¼ö¼ú ¹× ÀÓÇöõÆ® ¼ö¼ú Áõ°¡°¡ Ä¡°ú ¹× ±¸°­ ¿Ü°ú ¿ëµµÀÇ Á¦Ç° ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ÀÖ½À´Ï´Ù. WHO°¡ 2023³â 3¿ù¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ±¸°­ÁúȯÀÇ ¼¼°è À¯º´ÀÚ ¼ö´Â ¾à 35¾ï ¸íÀÔ´Ï´Ù. °Ô´Ù°¡ ±¸°­¾Ï¿¡ ÀÇÇÑ ±¸°­ ¼ö¼ú °Ç¼ö Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Global Cancer Observatory¿¡ µû¸£¸é 2022³â¿¡´Â 389,495°ÇÀÇ ÀÔ¼ú¾Ï°ú ±¸°­¾ÏÀÌ »õ·Ó°Ô ¹ß°ßµÇ¾ú½À´Ï´Ù.

º»¿Î½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ºñÈí¼ö¼º »À Á¦Ç° ºÎ¹®Àº Á¤Çü¿Ü°ú ¹× µÎ°³ ¾È¸é ¼ö¼ú¿¡ Àû¿ëÇÏ¿© 2023³â 65.0% ÀÌ»óÀÇ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. Èí¼ö¼º »À Á¦Ç° ºÎ¹®Àº °üÀý¼ºÇü¼ú¿¡¼­ ÀÌ·¯ÇÑ Á¦Ç°ÀÇ ³ôÀº ä¿ëÀ¸·Î 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Á¤Çü¿Ü°ú ºÎ¹®Àº 2023³â ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇϸç Á¤Çü¿Ü°ú ÁúȯÀ» ¾Î°í ÀÖ´Â ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • õ¿¬ ¼ÒÀç ºÎ¹®Àº 2023³â¿¡ ½ÃÀåÀ» µ¶Á¡ÇÏ¿´°í, ½ÅüÀÇ ÀÚ¿¬ Ä¡À¯ ¸ÞÄ¿´ÏÁò°úÀÇ ÀûÇÕ¼ºÀ¸·Î ÀÎÇØ 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • º´¿øÀÇ ÃÖÁ¾ ¿ëµµ ºÐ¾ß´Â Á¾ÇÕÀûÀÎ °Ç°­ °ü¸® ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ¿ªÇÒ·Î ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿Ü·¡ ȯÀÚ ½Ã¼³ ºÎ¹®Àº ¿Ü·¡ ȯÀÚ ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô±â ¶§¹®¿¡ 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ½ºÆ÷Ã÷ ¹× ·¹Å©¸®¿¡ÀÌ¼Ç È°µ¿¿¡ ´ëÇÑ Àα¸ Âü¿© Áõ°¡, ÀÌ¿¡ µû¸¥ °ñÀý Áõ·Ê Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î 2023³â ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù.
  • 2023³â 9¿ù, Abirx, Inc.´Â ½ÉÀå ÈäºÎ ¼ö¼ú¿¡ »ç¿ëµÇ´Â MONTAGE Settable Bone PuttyÀÇ ¹Ì±¹ FDA¿¡ ÀÇÇÑ ±ÔÁ¦ ´ç±¹ Çã°¡¸¦ ÃëµæÇß½À´Ï´Ù. FDA¿¡ ÀÇÇÑ Èä°ñÀý°³¼ú¿¡¼­ÀÇ ¼¼ÅÍºíº» ÆÛƼÀÇ »ç¿ë Çã°¡´Â ÀÌ°ÍÀÌ Ã³À½ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå º»¿Î½º ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • º»¿Î½º ½ÃÀå ºÐ¼® µµ±¸
    • ¾÷°è ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå º»¿Î½º ½ÃÀå : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ º»¿Î½º ½ÃÀå º¯µ¿ ºÐ¼® : Á¦Ç°º°(2023³â, 2030³â)
  • Á¦Ç°º° ¼¼°èÀÇ º»¿Î½º ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • Èí¼ö¼º º»¿Î½º
  • ºñÈí¼ö¼º º»¿Î½º

Á¦5Àå º»¿Î½º ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ º»¿Î½º ½ÃÀå º¯µ¿ ºÐ¼® : ¿ëµµº°(2023³â, 2030³â)
  • ¿ëµµº° ¼¼°èÀÇ º»¿Î½º ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • Á¤Çü ¿Ü°ú
  • ÈäºÎ ¿Ü°ú
  • ³ú½Å°æ ¿Ü°ú
  • Ä¡°ú ¹× ±¸°­ ¿Ü°ú
  • ±âŸ

Á¦6Àå º»¿Î½º ½ÃÀå : Àç·áº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ º»¿Î½º ½ÃÀå º¯µ¿ ºÐ¼® : Àç·áº°(2023³â, 2030³â)
  • Àç·áº° ¼¼°èÀÇ º»¿Î½º ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • õ¿¬ º»¿Î½º
  • ÇÕ¼º º»¿Î½º

Á¦7Àå º»¿Î½º ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ º»¿Î½º ½ÃÀå º¯µ¿ ºÐ¼® : ÃÖÁ¾ ¿ëµµº°(2023³â, 2030³â)
  • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ º»¿Î½º ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • º´¿ø
  • ¿Ü·¡½Ã¼³

Á¦8Àå º»¿Î½º ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°èÀÇ Áö¿ªº° ½ÃÀå ÇöȲ
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â) :
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîƼ³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • UAE
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ ¹× ¿µÇ⠺м®
  • ȸ»ç ¹× °æÀïÀÇ ºÐ·ù
  • º¥´õ »óȲ
    • Key customers
    • Key company market share analysis(2023)
    • Braun Melsungen AG
    • Baxter International Inc.
    • Johnson &Johnson
    • Medtronic plc
    • GPC Medical Ltd
    • Medline Industries Inc
    • Dolphin Sutures
    • SMI AG
    • ORION SUTURES INDIA PVT LTD
    • Universal Sutures
AJY 24.03.21

Bone Wax Market Growth & Trends:

The global bone wax market size is anticipated to reach USD 66.0 million by 2030, registering a CAGR of 3.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of fractures globally is the major factor driving product usage. Osteoporosis is one of the major risk factors resulting in fractures, especially in the hip, wrist, or spine. According to the International Osteoporosis Foundation, by 2050, the Asian population is expected to have over 50% prevalence of osteoporosis. Hence, increasing osteoporosis prevalence is expected to contribute to the market growth. Furthermore, the increasing prevalence of arthritis is expected to drive industry growth. Arthritis results in degrading bone quality, which further increases the risk of fractures. According to the Institute for Health Metrics and Evaluation, by 2050, the global prevalence of osteoarthritis, a common form of arthritis, is expected to reach 1 billion.

According to the Elsevier B.V. (Science Direct) study published in February 2021, in the UK, the prevalence of fractures in osteoarthritis individuals was 13.2 per 1000 individuals, whereas, in non-osteoarthritis individuals, the prevalence was 8.5 per 1000 individuals. Increasing dental health awareness and a growing number of reconstructive and implant surgeries fuel product demand in dental/oral surgery applications. According to the WHO article published in March 2023, the global prevalence of oral diseases is approximately 3.5 billion. Moreover, the rising volume of oral surgeries due to oral cancer is expected to drive market growth. For instance, according to the Global Cancer Observatory, in 2022, 389,495 new cases of lip and oral cancer were detected.

Bone Wax Market Report Highlights:

  • The non-absorbable bone product segment led the market with a share of more than 65.0% share in 2023 owing to its application in orthopedics and craniofacial surgeries. The absorbable bone segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the high adoption of these products in arthroplasty procedures
  • The orthopedic surgery segment held the largest revenue share in 2023 and is expected to grow at the fastest CAGR from 2024 to 2030 due to rising geriatric population suffering from orthopedic disorders
  • The natural material segment dominated the market in 2023 and is expected to grow at the fastest CAGR from 2024 to 2030 owing to its compatibility with the body's natural healing mechanisms
  • The hospital end-use segment dominated the market owing to its role in the delivery of comprehensive healthcare services. The outpatient facility segment is expected to register the fastest CAGR from 2024 to 2030 due to the high demand for outpatient surgeries
  • North America led the market in 2023 due to factors such as the growing participation of the population in sports and recreational activities, and a resultant rise in the cases of bone fractures
  • In September 2023, Abyrx, Inc. received a regulatory clearance from the U.S. FDA for its MONTAGE Settable Bone Putty, used in cardiothoracic surgery. It is the first clearance by the FDA to use settable bone putty in sternotomy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Material
    • 1.2.4. End-use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Material outlook
    • 2.2.4. End-use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Bone Wax Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing incidence of sport-related injuries
      • 3.2.1.2. Increasing prevalence of orthopedic disorders
      • 3.2.1.3. Growing geriatric population and increasing adoption of absorbable bone wax products in arthroplasty procedures
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High development and maintenance costs
  • 3.3. Bone Wax Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Bone Wax Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Bone Wax Market Movement Analysis, by Product (2023 & 2030)
  • 4.3. Global Bone Wax Market by Product Outlook (2018 - 2030) (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Absorbable bone wax
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Non-absorbable bone wax
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Bone Wax Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Bone Wax Market Movement Analysis, by Application (2023 & 2030)
  • 5.3. Global Bone Wax Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Orthopedic surgery
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Thoracic surgery
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Neurosurgery
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Dental/oral surgery
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Bone Wax Market: Material Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Bone Wax Market Movement Analysis, by Material (2023 & 2030)
  • 6.3. Global Bone Wax Market by Material Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Natural bone wax
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Synthetic bone wax
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Bone Wax Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Bone Wax Market Movement Analysis, by End Use (2023 & 2030)
  • 7.3. Global Bone Wax Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospitals
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Outpatient facilities
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Bone Wax Market: Regional Estimates & Trend Analysis, by Product, Application, Material, and End Use 2018 - 2030 (USD Million)

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key customers
    • 9.3.2. Key company market share analysis, 2023
    • 9.3.3. Braun Melsungen AG
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Baxter International Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Johnson & Johnson
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Medtronic plc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. GPC Medical Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Medline Industries Inc
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Dolphin Sutures
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. SMI AG
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. ORION SUTURES INDIA PVT LTD
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Universal Sutures
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦